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Abstract: In vitro pharmacokinetic studies were conducted on enantiomer pairs of twelve vali-
nate or tert-leucinate indole and indazole-3-carboxamide synthetic cannabinoid receptor agonists
(SCRAs) detected on the illicit drug market to investigate their physicochemical parameters and
structure-metabolism relationships (SMRs). Experimentally derived Log D7.4 ranged from 2.81
(AB-FUBINACA) to 4.95 (MDMB-4en-PINACA) and all SCRAs tested were highly protein bound,
ranging from 88.9 ± 0.49% ((R)-4F-MDMB-BINACA) to 99.5 ± 0.08% ((S)-MDMB-FUBINACA). Most
tested SCRAs were cleared rapidly in vitro in pooled human liver microsomes (pHLM) and pooled
cryopreserved human hepatocytes (pHHeps). Intrinsic clearance (CLint) ranged from 13.7 ± 4.06
((R)-AB-FUBINACA) to 2944 ± 95.9 mL min−1 kg−1 ((S)-AMB-FUBINACA) in pHLM, and from
110 ± 34.5 ((S)-AB-FUBINACA) to 3216 ± 607 mL min−1 kg−1 ((S)-AMB-FUBINACA) in pHHeps.
Predicted Human in vivo hepatic clearance (CLH) ranged from 0.34 ± 0.09 ((S)-AB-FUBINACA)
to 17.79 ± 0.20 mL min−1 kg−1 ((S)-5F-AMB-PINACA) in pHLM and 1.39 ± 0.27 ((S)-MDMB-
FUBINACA) to 18.25 ± 0.12 mL min−1 kg−1 ((S)-5F-AMB-PINACA) in pHHeps. Valinate and
tert-leucinate indole and indazole-3-carboxamide SCRAs are often rapidly metabolised in vitro but
are highly protein bound in vivo and therefore predicted in vivo CLH is much slower than CLint.
This is likely to give rise to longer detection windows of these substances and their metabolites in
urine, possibly as a result of accumulation of parent drug in lipid-rich tissues, with redistribution
into the circulatory system and subsequent metabolism.
Keywords: new psychoactive substances; synthetic cannabinoid receptor agonists; in vitro metabolism;
in vivo prediction; pharmacokinetics
1. Introduction
Synthetic cannabinoid receptor agonists (SCRAs) are a diverse group of new psychoac-
tive substances (NPS) that bind to, and activate, human cannabinoid receptors (CB1 and
CB2) [1,2]. More than 200 of these compounds have been reported on the illicit market to
date [3,4]. SCRA intoxications have been linked to a variety of adverse effects and have
been implicated in drug intoxication and drug death cases worldwide [5,6]. The exact
mechanisms of many of their harmful effects remain unclear, although some, at least, are
mediated via the CB1 receptor [7–11]. The intensity and duration of the physiological and
psychoactive effects experienced by users of SCRAs will be influenced by their pharma-
codynamics and pharmacokinetics, as well as other factors such as the dose, presence
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of co-ingested substances and individual factors such as sex and underlying health sta-
tus [11]. Commonly, the actual drug present and its concentration in a preparation will
be unknown to the user. Pharmacokinetics and pharmacodynamics will vary between
SCRA structural classes [12–21], being influenced by physicochemical properties related to
structural features.
The chemical structures of the SCRAs discussed in this study, including a representa-
tion showing the four constituent structural subunits (head, linker, core, tail), are provided
in Figure 1 and are referred to by numbers in bold in parenthesis throughout the text.
Amongst the most prevalent and potent SCRAs are the valinate and tert-leucinate indole
and indazole-3-carboxamides. These include AMB-FUBINACA (1) (MMB-FUBINACA;
methyl [1-(4-fluorobenzyl)-1H-indazole-3-carbonyl]valinate), 5F-MDMB-PINACA (2) (5F-
ADB; methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate),
5F-MDMB-PICA (3) (methyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3,3-
dimethylbutanoate), 4F-MDMB-BINACA (4) (4F-ADB, 4F-MDMB-BUTINACA; methyl
2-[1-(4-fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate) and MDMB-4en-
PINACA (5) (5-CL-ADB-A; methyl 3,3-dimethyl-2-[1-(pent-4-en-1-yl)-1H-indazole-3-
carboxamido] butanoate) [22–25].
SCRAs have been detected on the illicit market as pure substances, but are more com-
monly detected following infusion into herbal materials, papers and e-liquids for smoking
and vaping [22,26–28]. Valinate and tert-leucinate indole and indazole-3-carboxamide
SCRAs are chiral compounds, and in all SCRAs studied to date, the (S)-enantiomer is signif-
icantly more potent than the (R)-enantiomer. Chiral profiling data indicate that the SCRAs
detected in the majority of samples tested are essentially enantiopure (S)-enantiomer how-
ever the presence of up to 16% (R)-enantiomer has been reported in a small number of
cases [1,29–31].
An understanding of the physicochemical parameters underpinning the behavior
of SCRAs in biological systems, their pharmacokinetics and their effects is essential. For
example, the proportion of the SCRA dose that is not plasma protein-bound (the free drug)
will be responsible for the drug’s pharmacological effects. This unbound fraction will also
be available for metabolism by hepatic and, potentially, extrahepatic enzymes. Whilst a
great deal is known about the pharmacokinetics of naturally occurring cannabinoids such
as ∆9-tetrahydrocannabinol (THC) [32–36] and its metabolites, less is known about the
pharmacokinetics of the valinate and tert-leucinate indole and indazole-3-carboxamide
SCRAs [37–39]. Like SCRAs, the most common routes of administration of THC are
smoking and vaping. THC is more bioavailable via inhalation compared to ingestion,
and inhalation avoids first-pass metabolism leading to rapid onset of psychoactive ef-
fects [34,36]; is highly lipophilic (log P = 6.7 [39]) and has a low distribution into erythro-
cytes and a high plasma protein affinity (95–99% protein-bound in plasma) [33]. Synthetic
cannabinoids are also lipophilic, with theoretical log P values in the literature ranging
from 3.02–8.14 [18–21], although theoretical log P values reported for the valinate and
tert-leucinate indole-/indazole-3-carboxamides indicate that they are amongst the least
lipophilic of the SCRAs.
THC is distributed into the adipose tissue, especially in chronic users, with subsequent
slow release from the adipose leading to long detection windows for THC and its metabo-
lites [33,36,40]. Many SCRAs are also highly lipophilic; JWH-210 (4-ethylnaphthalen-
1-yl-(1-pentylindol-3-yl)methanone) (log P = 7.5) and RCS-4 (2-(4-methoxyphenyl)-1-(1-
pentyl-indol-3-yl)methanone) (log P = 5.6) have shown similar distribution to THC into the
adipose tissue of experimentally exposed pigs [39], and long detection windows for other
SCRAs in humans have also been reported [41–43]. However, lipophilicity is not the only
determining factor for uptake by adipocytes [39], as some highly lipophilic drugs are not
extensively distributed into adipose tissue [44,45] and structural features are also thought
to contribute [46,47].
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MDMB-4en-PINACA; (6) MDMB-FUBINACA; (7) AMB-4en-PICA; (8) AB-FUBINACA; (9) AMB-
CHMICA; (10) 5F-AMB-PINACA; (11) AB-CHMINACA; (12) MDMB-4en-PICA. Asterisk (*) indi-
cates chiral centre. Numbering used in the Figure reflects the order in which structures are men-
tioned in the text. 
Castaneto et al. (2015) provided a thorough review of the pharmacokinetics of earlier 
emerging SCRAs [12]; however, limited/estimated human in vivo pharmacokinetic data 
are available for currently prevalent SCRAs. The available data from in vivo pharmacoki-
netic studies for valinate and tert-leucinate indole-/indazole-3-carboxamides are based ei-
ther on long-term abstinence monitoring in casework from users reported to have smoked 
or vaped the substances and then abstained from their use [43], or on small scale self-
administration studies where the drug is ingested rather than smoked or vaped and this 
does not reflect user behaviour or chronic use [43,48–50]. 
i Structures of synthetic ca nabinoid r ceptor agonists (SCRAs) involved in this study.
(1) AMB-FUBIN CA; (2) 5F-MDMB-PINACA; (3) 5F-MDMB-PICA; (4) 4F- - I ; (5)
MDMB-4en-PINACA; (6) MDMB-FUBINACA; (7) AMB-4en-PICA; (8) AB-FUBINACA; (9) AMB-
CHMICA; (10) 5F-AMB-PINACA; (11) AB-CHMINACA; (12) MDMB-4en-PICA. Asterisk (*) indicates
chiral centre. Numbering used in the Figure reflects the order in which structures are mentioned in
the text.
Castaneto et al. (2015) provided a thorough review of the pharmacokinetics of ear-
lier emerging SCRAs [12]; however, limited/estimated human in vivo pharmacokinetic
data are available for currently prevalent SCRAs. The available data from in vivo phar-
macokinetic studies for valinate and tert-leucinate indole-/indazole-3-carboxamides are
based either on long-term abstinence monitoring in casework from users reported to have
smoked or vaped the substances and then abstained from their use [43], or on small scale
self-administration studies where the drug is ingested rather than smoked or vaped and
this does not reflect user behaviour or chronic use [43,48–50].
Our understanding of the structure-activity relationships (SARs) and structure-
metabolism relationships (SMRs) of the valinate and tert-leucinate indole and indazole-3-
carboxamide SCRAs is increasing, and phase I metabolite formation is well characterised
in vitro [1,2,18,23,31,37,38,51–55]. A valuable systematic study of the SMRs of valinate and
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tert-leucinate indole- and indazole-3-carboxamide SCRAs using pHLM has recently been
published [37]. In SCRAs where a valine (dimethyl) methyl ester (AMB-) head group is
present, the most abundant metabolite formed is the carboxylic acid metabolite; where a tert-
leucine (trimethyl) methyl ester (MDMB-) head group is present the carboxylic acid metabo-
lite is formed but is rarely the most abundant metabolite in vitro (MDMB-FUBINACA (6)
(methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate) is an
exception, probably due to the metabolic stability of the fluorobenzyl moiety). Where a
valinamide (dimethyl) (AB-) head group is present, the carboxylic acid metabolite is formed
to a greater extent when an indazole core is also present, compared to an indole core, but is
never the principal metabolite. Where a tert-leucinamide (trimethyl) (ADB-) head group
is present the carboxylic acid metabolite is only ever a minor metabolite in vitro, with
the most prevalent metabolite determined by the relative lability of the other structural
features present [37]. Oxidative defluorination of 5F-MDMB-PINACA (2), forming a major
metabolite in vitro and in vivo, has been shown to occur in HLM without the presence of
NADPH, suggesting the involvement of non-CYP enzymes [54]. The phase I metabolism of
4F-MDMB-BINACA (4) has recently been described [55] and was found to involve several
cytochrome P450 and human carboxylesterase 1 (CES-1) isoforms, with the carboxylic acid
metabolite and formation of a lactone among the most abundant metabolites.
Recently, valinate and tert-leucinate indole and indazole-3-carboxamide SCRAs with
alkene ‘tail’ groups (MDMB-4en-PINACA (5) and AMB-4en-PICA (7) (MMB-4en-PICA,
MMB-022; methyl 3-methyl-2-[(1-pent-4-enylindole-3-carbonyl)amino] butanoate)) have
been detected on the illicit market and in toxicological samples [56,57]. Metabolite identifi-
cation studies of such SCRAs and other drugs containing an alkene moiety have demon-
strated the in vitro formation of a dihydrodiol metabolite (via epoxidation catalysed by
CYP isoenzymes, followed by hydration of the epoxide likely facilitated by CYP enzymes
and epoxide hydrolase [56,58,59]), and specifically for SCRAs the formation of the car-
boxylic acid metabolite (through ester hydrolysis), and a carboxylic acid with dihydrodiol
metabolite [56]. The carboxylic acid metabolite of MDMB-4en-PINACA (5) was the only
metabolite detected in blood taken for toxicological analysis from an authentic user, whilst
both the carboxylic acid and carboxylic acid with dihydrodiol metabolites were detected
in urine. Studies have shown that the carboxylic acids are formed in vitro without the
presence of NADPH [54,60,61], and their hepatic formation is thought to be mediated by
carboxylesterases, principally CES-1 [55,61,62]. However, interpretation of the detection of
carboxylic acid metabolites in plasma in isolation, formed by hydrolysis of the methyl ester
and amide moieties, should be treated cautiously. Some SCRAs have been shown to be
unstable in human blood when samples have not been frozen prior to analysis [63–65], and
carboxylesterases are not present in human blood [66,67]. The presence of the carboxylic
acid metabolites of these and similar SCRAs in blood could therefore be explained, at least
in part, by non-enzymatic hydrolysis or by the action of other plasma esterases prior to,
or during, storage, rather than as a result of the recirculation of Phase I metabolites in the
body after formation, primarily in the liver [64,67,68].
This study aims to increase understanding of the factors influencing the metabolism
and pharmacokinetics of valinate or tert-leucinate indole- and indazole-3-carboxamide
SCRAs. Their lipophilicity (Log P/Log D7.4) was determined using both in silico methods
and experimentally; their short-term stability in plasma has been assessed in vitro under
physiological conditions; and their plasma protein binding (PPB) values were determined
experimentally for the first time. In vitro intrinsic clearance was calculated following
incubation with pooled human liver microsomes (pHLM) and pooled human cryopre-
served hepatocytes (pHHeps) for 12 SCRA enantiomer pairs, to investigate the structural
and conformational features influencing their interaction with metabolic enzymes and
their metabolic clearance rates. In vitro pharmacokinetic data were then used to estimate
in vivo human hepatic clearance and hepatic extraction ratios, thus helping to predict their
pharmacokinetics in a manner relevant to toxicological casework.
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2. Results and Discussion
2.1. Lipophilicity
Theoretical log P values were calculated for the 12 SCRAs included in this study
(Figure 1) using a range of software packages (see Section 3 for details), and the chro-
matographic hydrophobicity index (CHI) log D at pH 7.4 (Log D7.4) was determined
experimentally for each (S)-enantiomer for comparison. As the tested SCRAs are non-
ionizable, log P and log D7.4 are equivalent. Although predicted values varied between in
silico prediction packages, the ranking of compounds was comparable. AB-FUBINACA
(8) (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)
was the least lipophilic SCRA tested (Log P range = 2.66–3.24) with AMB-CHMICA (9)
(methyl [1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate) the most lipophilic (Log
P range = 3.84–5.51) (Table 1). The predicted data are similar to previously reported
in silico data for valinate and tert-leucinate indole and indazole-3-carboxamide SCRAs
(2.29–3.81) [19], calculated using ChemBioDraw (Cambridge Soft Corporation, Cam-
bridge, MA, USA).
Table 1. Predicted Log P and experimentally derived Log D7.4 values for test SCRAs calculated using a chromatographic
hydrophobicity index (CHI). SwissADME data are shown, with log P ranges obtained using Gastroplus, MoKa, Canvas and
XlogP software provided for comparison (see Section S2 of the supplementary information for full data set). Data for the
azaindole-3-carboxamide SCRA, 5F-AB-P7AICA are shown for comparative purposes.
Compound Experimental Log D7.4
SwissADME Predicted
Log P
Log P Range from Other Software
Packages
MDMB-4en-PINACA (5) 4.95 3.41 3.61–4.00
AMB-CHMICA (9) 4.77 3.84 4.30–5.51
MDMB-FUBINACA (6) 4.69 3.83 4.08–4.24
5F-MDMB-PINACA (2) 4.50 3.63 3.76–3.90
MDMB-4en-PICA (12) 4.40 3.77 3.98–4.98
AMB-FUBINACA (1) 4.28 3.50 3.75–4.09
4F-MDMB-BINACA (4) 4.18 3.39 3.33–3.40
5F-AMB-PINACA (10) 4.07 3.41 3.31–3.64
5F-MDMB-PICA (3) 4.06 3.98 4.10–4.90
AMB-4en-PICA (7) 3.97 3.53 3.50–4.83
AB-CHMINACA (11) 3.71 2.91 3.10–3.55
AB-FUBINACA (8) 2.81 2.80 2.66–3.24
5F-AB-P7AICA - 2.45 1.57–2.74
Experimental log D7.4 values (Table 1) ranged from 2.81 (AB-FUBINACA (8)) to 4.95
(MDMB-4en-PINACA (5)). Theoretical log P values for SCRAs with an indole core were
consistently higher than those with an indazole core. However, this was not the case
with the experimentally derived data. Predictions were in the closest agreement for 5F-
MDMB-PICA (3) and AB-FUBINACA (8). For all other compounds, experimental values
were generally under-predicted by in silico methods. With the exception of MDMB-4en-
PINACA (5), which was the most lipophilic SCRA studied according to experimental data,
all predicted values were within one log unit of experimental values.
It has been reported that it may not be possible to detect parent SCRAs with a log P
of 4–5 or greater in urine [19]. The majority of parent valinate and tert-leucinate indole
and indazole-3-carboxamide SCRAs in this study have log P or log D values at or below
this range; they have often been detected in urine, but usually as a very small propor-
tion compared to their metabolites [43,64,69–73]. However, a recent study, involving the
oral consumption of the 7-azaindole valinamide-based SCRA, 5F-AB-P7AICA, unusually
identified the parent compound as the major component present in urine [50]. Although
not included in this study, this SCRA was estimated to have an average theoretical log P
value of 2.15 ± 0.46 (Table 1) and so was the least lipophilic molecule measured. This may
explain why the parent drug is detected in urine at a higher proportion than its metabolites.
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In addition, it has been postulated that the presence of an azaindole core structure may
decrease the extent to which metabolism occurs at other sites on the structure [50].
2.2. Plasma Stability Studies
The instability of valinate and tert-leucinate indole and indazole-3-carboxamide SCRAs
in unfrozen whole blood and plasma samples has been reported previously [37,38,63], whilst
other somewhat contradictory reports have shown long-term stability for some analogs
(315 days) at temperatures of up to 20 ◦C in human plasma [65]. The stability of the majority
of the SCRAs described in this study in pooled human plasma (some (R)-enantiomers
were not tested) over three to five hours under physiological conditions (37 ◦C, pH 7.4)
was assessed prior to carrying out the five-hour long PPB studies. Procaine, the positive
control, had a half-life of 6.5 min with no esterase inhibitors present, in line with other
reports and the values expected in our laboratory [74,75], and was stable when plasma was
pre-incubated with esterase inhibitors.
Over 85% of the parent compound remained following three hours of incubation
(Table 2 and Figure 2, with figures for all compounds studied shown in Section S5 of the
supplementary information).
No structure-stability relationship was observed, there was no difference in the stabil-
ity between enantiomers, and there was no substantial difference between the incubations
with or without inhibitors over the three-hour stability study. The plasma stability of (S)-
AMB-FUBINACA (1) was tested for five hours, the time used in this study for PPB studies,
due to its previously reported instability in casework [63]. After five hours, 94 ± 0.1%
(n = 3) of the compound remained when incubated with esterase inhibitors, and 86 ± 4.0%
(n = 4) when incubated without esterase inhibitors. This suggests that AMB-FUBINACA
may be degraded by plasma esterases over extended time periods, however further study
using a longer plasma incubation time is required.
Table 2. Short-term plasma stability of tested SCRAs and positive control (procaine). a indicates data
for 5 h incubations.
Compound
Parent Compound Remaining (%)
(3 h; a 5 h)
No Esterase Inhibitors n = Esterase Inhibitors n =
Procaine (control) 0.03 ± 0.02; a 0.08 ± 0.11 5 98.3 ± 8.0; a 91.0 ± 1.7 5
(S)-AB-FUBINACA (8) 104.4 ± 1.1 3 102.7 ± 2.5 3
(S)-AB-CHMINACA (11) 98.2 ± 7.2 3 97.9 ± 7.0 3
(S)-5F-MDMB-PICA (3) 97.3 ± 6.4 3 99.5 ± 5.8 3
(R)-5F-MDMB-PICA (3) 103.2 ± 14.5 3 97.7 ± 5.6 3
(S)-AMB-FUBINACA (1) 96.6 ± 3.8; a 85.9 ± 4.0 4 96.1 ± 1.6; a 93.5 ± 0.1 3
(S)-MDMB-4en-PINACA (5) 94.8 ± 0.7 3 89.0 ± 3.3 3
(R)-MDMB-4en-PINACA (5) 87.2 ± 6.9 3 89.4 ± 3.4 3
(S)-MDMB-FUBINACA (6) 94.2 ± 6.3 3 91.6 ± 2.2 3
(S)-AMB-CHMICA (9) 93.9 ± 9.3 3 90.5 ± 3.4 3
(S)-4F-MDMB-BINACA (4) 93.1 ± 5.1 3 96.0 ± 2.9 3
(R)-4F-MDMB-BINACA (4) 91.1 ± 6.8 3 96.0 ± 1.7 3
(S)-5F-AMB-PINACA (10) 93.0 ± 6.1 3 89.8 ± 1.5 3
(S)-AMB-4en-PICA (7) 92.6 ± 8.3 3 95.6 ± 6.8 3
(R)-AMB-4en-PICA (7) 91.7 ± 1.9 3 95.5 ± 2.9 3
(S)-5F-MDMB-PINACA (2) 92.5 ± 10.2 7 97.0 ± 1.1 3
(R)-5F-MDMB-PINACA (2) 95.9 ± 6.7 6 100.1 ± 7.0 7
(S)-MDMB-4en-PICA (12) 91.5 ± 8.6 3 89.4 ± 2.3 3
(R)-MDMB-4en-PICA (12) 90.3 ± 5.4 3 87.7 ± 11.0 3
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2.3. Plasma Protein Binding (PPB) 
The experimentally derived PPB values for the majority of SCRAs in this study are 
shown in Table 3 (some (R)-enantiomers were not tested due to reference standard avail-
ability). All SCRAs were highly protein bound, with PPB ranging from 88.9–99.5%. For 
the positive controls, warfarin and nicardipine, binding values were 98.4% and 97.7%, re-
spectively, in agreement with literature data [77,78]. The observed binding of the SCRAs 
reported in this study were in line with plasma protein binding data previously reported 
for THC [33] and is related to the lipophilicity of the SCRAs tested [13,79]. Thermal stabil-
ity controls, which consisted of spiked plasma stored at 4 °C and 37 °C for the duration of 
the experiment, showed that most compounds remained stable (total peak area in dia-
lysed sample >95% of the peak area in the non-dialysed sample). SCRAs for which recov-
ery (total peak area in dialysed samples) was ≤95% that of 4 °C samples were all valine 
methyl ester (AMB-) compounds ((S)-AMB-FUBINACA (1) recovery = 77 ± 4.4%, n = 3; 
(R)-AMB-4en-PICA (7) recovery = 95 ± 2.0%, n = 3). This agrees with available plasma 
stability data for the 3- and 5-h incubations reported here and with published long-term 
stability studies [63,65]. These findings all support the view that SCRAs containing a va-
line methyl ester head group are less stable in plasma than those containing a tert-leucine 
methyl ester or tert-leucinamide/valinamide head group.  
As the equilibrium dialysis method employed to determine PPB involves the meas-
urement of the ratio of bound to unbound analyte at the end of the equilibration period, 
the instability observed for the valine methyl ester SCRAs will not affect the calculated 
binding value [80]. 
Figure . t ilit of SCRAs (a) (S)-AMB-FUBINACA (1); (b) (S)-4F-MDM -BINACA (4); (c) (S)-
AB-CHMINACA (11); (d) (S)- DMB-4en-PICA (12) in pooled human plasma in the presence and
absence of esterase enzyme (n ≥ 3 ± SD). Full data in Section S5 of the supplementary information.
The instability of methyl ester containing SCRAs in plasma has previously been linked
to the presence of CES-1 enzymes [76], however, whilst present in the liver and lung, CES-1
is not present in human plasma [66,67]. Huma plasma contains other esterases such as
butyrylcholinesterase (BchE), paraoxonase (PON-1), albumin esterase (a ‘pseudo-esterase’)
and acetylcholinesterase (AchE) [66–68] and therefore it is these enzymes that may be
involved in the degradation of SCRAs with methyl ester moieties, although non-enzymatic
hydrolysis may also be involved [64].
2.3. Plasma Protein Binding (PPB)
The experimentally derived PPB values for the majority of SCRAs in this study
are shown in Table 3 (some (R)-enantiomers were not tested due to reference standard
availability). All SCRAs were highly protein bound, with PPB ranging from 88.9–99.5%.
For the positive controls, warfarin and nicardipine, binding values were 98.4% and 97.7%,
respectively, in agreement with literature data [77,78]. The observed binding of the SCRAs
reported in this study were in line with plasma protein binding data previously reported
for THC [33] and is related to the lipophilicity of the SCRAs tested [13,79]. Thermal stability
controls, which consisted of spiked plasma stored at 4 ◦C and 37 ◦C for the duration of the
experiment, showed that most compounds remained stable (total peak area in dialysed
sample >95% of the peak area in the non-dialysed sample). SCRAs for which recovery
(total peak area in dialysed samples) was ≤95% that of 4 ◦C samples were all valine methyl
ester (AMB-) compounds ((S)-AMB-FUBINACA (1) recovery = 77 ± 4.4%, n = 3; (R)-AMB-
4en-PICA (7) recovery = 95 ± 2.0%, n = 3). This agrees with available plasma stability
data for the 3- and 5-h incubations reported here and with published long-term stability
studies [63,65]. These findings all support the view that SCRAs containing a valine methyl
ester head group are less stable in plasma than those containing a tert-leucine methyl ester
or tert-leucinamide/valinamide head group.
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Table 3. Plasma protein binding (PPB) of tested SCRA enantiomers.
Compound PPB (%) Fraction Unbound (fu) n =
(S)-MDMB-FUBINACA (6) 99.5 ± 0.08 0.005 ± 0.0008 3
(S)-MDMB-4en-PINACA (5) 99.0 ± 0.01 0.010 ± 0.0001 3
(R)-MDMB-4en-PINACA (5) 98.1 ± 0.71 0.019 ± 0.0071 3
(S)-AMB-CHMICA (9) 98.8 ± 0.06 0.012 ± 0.0006 3
(S)-AMB-FUBINACA (1) 98.1 ± 0.08 0.019 ± 0.0008 3
(S)-AB-FUBINACA (8) 97.9 ± 0.44 0.021 ± 0.0044 3
(S)-5F-MDMB-PINACA (2) 97.8 ± 0.19 0.022 ± 0.0019 3
(R)-5F-MDMB-PINACA (2) 96.0 ± 0.58 0.040 ± 0.0058 4
(S)-AB-CHMINACA (11) 97.2 ± 2.19 0.028 ± 0.0219 3
(S)-MDMB-4en-PICA (12) 96.5 ± 0.32 0.035 ± 0.0031 4
(R)-MDMB-4en-PICA (12) 94.7 ± 1.11 0.053 ± 0.0111 4
(S)-AMB-4en-PICA (7) 94.7 ± 0.37 0.053 ± 0.0037 3
(R)-AMB-4en-PICA (7) 94.1 ± 0.10 0.059 ± 0.0010 3
(S)-5F-AMB-PINACA (10) 94.2 ± 0.08 0.058 ± 0.0008 3
(S)-4F-MDMB-BINACA (4) 93.9 ± 0.28 0.061 ± 0.0028 3
(R)-4F-MDMB-BINACA (4) 88.9 ± 0.49 0.111 ± 0.0049 4
(S)-5F-MDMB-PICA (3) 93.8 ± 0.07 0.062 ± 0.0007 3
(R)-5F-MDMB-PICA (3) 93.8 ± 0.15 0.062 ± 0.0015 3
As the equilibrium dialysis method employed to determine PPB involves the mea-
surement of the ratio of bound to unbound analyte at the end of the equilibration period,
the instability observed for the valine methyl ester SCRAs will not affect the calculated
binding value [80].
2.4. In Vitro Intrinsic Clearance
The in vitro metabolic stability of the tested (S)- and (R)-SCRA enantiomers in pHLM
and pHHeps incubations are summarised in Tables 4 and 5, respectively. Each batch
of pHLM and pHHeps used in the study comprised pooled biological material from
50 donors, 25 male and 25 female, of varying ages and health status. Details of the
donors to each batch are provided in the certificate of analysis associated with each batch
(see Section 3.1 for further details of donors). It is recognized that there will be inter-
and intra-individual variation in SCRA metabolism, due to age, sex, health status and
polymorphisms [81]. The use of large donor pools for pHLM and pHHeps batches (n = 50)
reduces inter-batch variation and provides information on the fundamental structure
metabolism relationships of SCRA analogues within and between structural classes, and
intrinsic clearance rates obtained relate to the enzyme expression of an ‘average individual’.
This study does not set out to study differences in the ability of individuals, or phenotypes
to metabolise SCRAs. Positive controls included with all test batches showed acceptable
clearance; verapamil CLint in pHLM ranged from 153–360 mL min−1 kg−1, while CLint
in cryopreserved pHHeps ranged from 117–179 mL min−1 kg−1, within the expected
ranges for our laboratory and in line with literature reports [82–86]. Further positive
controls for pHHep incubations, 7-ethoxycoumarin and 7-hydroxycoumarin, provided
intrinsic clearance rates ranging from 55–305 mL min−1 kg−1 and 46–238 min−1 kg−1,
respectively. The ranges observed cover normal batch variation for the metabolism of
these compounds. Hepatocyte viability ranged from 90–94%. All compounds were initially
tested using a single pHHeps lot (HUE50-N, see Section 3.1 for further information on pool
donors), allowing determination of fundamental differences in metabolic stability between
compounds. A subset of compounds was further tested at a later date using pHHeps lot
HUE50-P. This gave an indication of potential between-batch variation, evident only for
(R)-5F-MDMB-PINACA (2). Intrinsic clearance and predicted in vivo data calculated using
alternative microsomal scaling factors and an alternative hepatocyte cell density reported
in the literature are provided for microsome and hepatocyte incubations in Sections S6 and
S7 of the supplementary information, respectively.
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Table 4. In vitro half-life, microsomal clearance (CLint micr) and intrinsic clearance (CLint) with predicted in vivo hepatic
clearance (CLH) and hepatic extraction ratio (EH) for pooled human liver microsome incubations (n ≥ 3 ± SD). As plasma




















(S)-AMB-FUBINACA (1) 0.6 ± 0.02 2.182 ± 0.071 2944 ± 95.9 15.27 ± 0.14 0.73 ± 0.006 3
(R)-AMB-FUBINACA (1) 5.9 ± 0.48 0.237 ± 0.020 320 ± 26.8 - - 6
(S)-5F-AMB-PINACA (10) 0.9 ± 0.07 1.494 ± 0.115 2016 ± 155.7 17.79 ± 0.20 0.85 ± 0.010 6
(R)-5F-AMB-PINACA (10) 6.5 ± 0.42 0.213 ± 0.014 288 ± 19.1 - - 6
(S)-AMB-CHMICA (9) 4.1 ± 0.75 0.343 ± 0.069 463 ± 92.9 4.37 ± 0.68 0.21 ± 0.032 3
(R)-AMB-CHMICA (9) 8.4 ± 1.0 0.167 ± 0.019 226 ± 25.4 - - 3
(S)-AMB-4en-PICA (7) 6.0 ± 1.0 0.236 ± 0.042 318 ± 56.6 9.29 ± 0.89 0.44 ± 0.042 10
(R)-AMB-4en-PICA (7) 4.1 ± 0.75 0.348 ± 0.068 469 ± 92.2 11.8 ± 0.97 0.56 ± 0.046 11
(S)-MDMB-4en-PINACA (5) 6.3 ± 1.0 0.226 ± 0.037 305 ± 49.3 2.66 ± 0.37 0.13 ± 0.018 7
(R)-MDMB-4en-PINACA (5) 5.5 ± 0.59 0.253 ± 0.026 341 ± 34.6 4.94 ± 0.39 0.24 ± 0.019 7
(S)-5F-MDMB-PINACA (2) 6.7 ± 0.31 0.207 ± 0.009 280 ± 12.8 4.76 ± 0.17 0.23 ± 0.008 5
(R)-5F-MDMB-PINACA (2) 8.0 ± 1.1 0.176 ± 0.024 237 ± 31.7 6.52 ± 0.61 0.31 ± 0.029 5
(S)-5F-MDMB-PICA (3) 9.0 ± 1.4 0.156 ± 0.027 211 ± 36.9 8.01 ± 0.84 0.38 ± 0.04 3
(R)-5F-MDMB-PICA (3) 11 ± 0.11 0.132 ± 0.001 178 ± 1.86 7.22 ± 0.05 0.34 ± 0.002 3
(S)-MDMB-4en-PICA (12) 8.5 ± 1.3 0.166 ± 0.024 224 ± 32.4 5.69 ± 0.61 0.27 ± 0.029 11
(R)-MDMB-4en-PICA (12) 5.4 ± 0.74 0.260 ± 0.040 350 ± 53.3 9.81 ± 0.75 0.47 ± 0.036 9
(S)-4F-MDMB-BINACA (4) 9.9 ± 1.9 0.143 ± 0.025 193 ± 33.8 7.51 ± 0.88 0.36 ± 0.042 3
(R)-4F-MDMB-BINACA (4) 14 ± 0.68 0.096 ± 0.005 130 ± 6.26 8.55 ± 0.24 0.41 ± 0.012 3
(S)-MDMB-FUBINACA (6) 11 ± 2.4 0.135 ± 0.030 183 ± 40.2 0.87 ± 0.18 0.04 ± 0.009 6
(R)-MDMB-FUBINACA (6) 20 ± 2.5 0.071 ± 0.009 95.4 ± 12.3 - - 6
(S)-AB-CHMINACA (11) 27 ± 2.9 0.051 ± 0.005 69.1 ± 7.35 1.77 ± 0.17 0.08 ± 0.008 3
(R)-AB-CHMINACA (11) 43 ± 5.0 0.033 ± 0.004 44.1 ± 4.89 - - 3
(S)-AB-FUBINACA (8) 118 ± 28 0.012 ± 0.003 16.4 ± 4.24 0.34 ± 0.09 0.02 ± 0.004 3
(R)-AB-FUBINACA (8) 145 ± 45 0.010 ± 0.003 13.7 ± 4.06 - - 3
Table 5. In vitro half-life and intrinsic clearance (CLint) with predicted in vivo hepatic clearance (CLH) and hepatic extraction
ratio (EH) for pooled human cryopreserved hepatocyte incubations (n ≥ 3 ± SD). As plasma protein values are not available
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(S)-AMB-FUBINACA (1) 2.5 ± 0.55 3216 ± 607 15.52 ± 0.85 0.74 ± 0.041 8
(R)-AMB-FUBINACA (1) 3.1 ± 0.57 2557 ± 463 - - 8
(S)-5F-AMB-PINACA (10) 3.2 ± 0.16 2404 ± 125 18.25 ± 0.12 0.87 ± 0.006 3
(R)-5F-AMB-PINACA (10) 4.7 ± 0.26 1623 ± 87.0 - - 3
(S)-AMB-4en-PICA (7) 6.9 ± 2.1 1205 ± 363 15.56 ± 1.24 0.74 ± 0.059 8
(R)-AMB-4en-PICA (7) 5.5 ± 2.1 1589 ± 616 16.79 ± 1.33 0.80 ± 0.063 8
(S)-AMB-CHMICA (9) 7.6 ± 0.35 1011 ± 48.5 7.68 ± 0.22 0.37 ± 0.011 3
(R)-AMB-CHMICA (9) 8.3 ± 0.35 918 ± 38.2 - - 3
(S)-MDMB-4en-PINACA (5) 12 ± 2.6 683 ± 158 5.11 ± 0.89 0.24 ± 0.042 7
(R)-MDMB-4en-PINACA (5) 22 ± 3.6 363 ± 66.5 5.16 ± 0.70 0.25 ± 0.033 7
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(S)-5F-MDMB-PINACA (2) 13 ± 3.3 604 ± 135 8.05 ± 1.15 0.38 ± 0.055 12
(R)-5F-MDMB-PINACA (2) 23 ± 1.8 334 ± 25.5 8.16 ± 0.38 0.39 ± 0.018 6
(S)-4F-MDMB-BINACA (4) 16 ± 0.74 466 ± 21.6 12.08 ± 0.23 0.58 ± 0.011 3
(R)-4F-MDMB-BINACA (4) 58 ± 17.2 139 ± 37.4 8.77 ± 1.43 0.42 ± 0.068 4
(S)-MDMB-FUBINACA (6) 26 ± 5.0 298 ± 62.7 1.39 ± 0.27 0.07 ± 0.013 3
(R)-MDMB-FUBINACA (6) 32 ± 5.4 239 ± 40.7 - - 3
(S)-MDMB-4en-PICA (12) 37 ± 6.9 213 ± 41.6 5.46 ± 0.78 0.26 ± 0.037 7
(R)-MDMB-4en-PICA (12) 44 ± 6.3 176 ± 24.0 6.42 ± 0.62 0.31 ± 0.029 7
(S)-5F-MDMB-PICA (3) 38 ± 4.6 204 ± 23.2 7.87 ± 0.58 0.37 ± 0.027 3
(R)-5F-MDMB-PICA (3) 54 ± 9.4 145 ± 24.1 6.27 ± 0.74 0.30 ± 0.035 3
(S)-AB-CHMINACA (11) 39 ± 8.8 210 ± 72.9 4.52 ± 1.12 0.22 ± 0.053 6
(R)-AB-CHMINACA (11) 38 ± 8.7 213 ± 54.3 - - 5
(S)-AB-FUBINACA (8) 76 ± 24 110 ± 34.5 2.06 ± 0.58 0.10 ± 0.028 8
(R)-AB-FUBINACA (8) 69 ± 11 113 ± 15.6 - - 8
2.4.1. Comparison of SCRA (S)-Enantiomer Intrinsic Clearance Rates and Half-Lives
The (S)-enantiomers of valinate and tert-leucinate indazole- and indole-3-carboxamide
SCRAs are known to be much more prevalent and more potent than the (R)-enantiomers
and are often more efficacious [1,31]. For the (S)-enantiomers tested in this study, the
order of the in vitro intrinsic clearance rate was AMB > MDMB > AB-compounds in both
pHLM and pHHeps (Tables 4 and 5; Figures 3 and 4). Data showing the clearance of
each enantiomer pair are provided in Sections S6 and S7 of the supplementary informa-
tion for pHLM and pHHeps, respectively). The in vitro half-lives of SCRAs in pHLM
incubations ranged from 118 ± 28 min for (S)-AB-FUBINACA (8) to 0.60 ± 0.02 min for
(S)-AMB-FUBINACA (1). In pHHeps, half-lives ranged from 76 ± 24 min for (S)-AB-
FUBINACA (8) and 2.50 ± 0.55 min for (S)-AMB-FUBINACA (1). In vitro pHLM intrinsic
clearance for some compounds (e.g., (S)-AMB-FUBINACA (1) and (S)-5F-AMB-PINACA
(10) (methyl [1-(5-fluoropentyl)-1H-indazole-3-carbonyl]valinate)) was so fast that it was
challenging to accurately calculate intrinsic clearance rates and half-lives (see Figures S22
and S32 in Section S6 of the supplementary information). The presence of a valinamide
head group (AB-compounds) increased drug half-life, slowing clearance compared to
SCRAs with a more labile methyl ester moiety (AMB- and MDMB-compounds). However,
AB-CHMINACA (11) (N-[1-amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-
indazole-3-carboxamide) clearance in hepatocytes was comparable to that of the slowest
cleared tert-leucine methyl ester (MDMB-) compounds, possibly due to the relative lability
of the cyclohexyl tail group to enzymatic attack [87]. tert-Leucine methyl ester (MDMB-
compounds), having a trimethyl moiety in the head group, are metabolised at a slower
rate than those with a dimethyl moiety in the head group (AMB-, valine methyl ester
compounds). This could be due to steric hindrance caused by the extra methyl group
adjacent to the methyl ester, one of the principal sites of biotransformation.
The differences in clearance rates between SCRA compounds which differ only by
their head group (AB-, AMB- and MDMB-compounds) and which had either a fluorobenzyl
tail group (FUBINACAs) or a fluoropentyl tail group (PINACAs) is illustrated in Figure 4.
Although no tert-leucinamide SCRAs (ADB-type SCRAs) were investigated in this
study, it might logically be concluded that their intrinsic clearance is likely to be similar
or even slower than the valinamide SCRAs (AB-type SCRAs), however this requires
further experimental confirmation. The in vitro clearance of SCRAs with indazole cores
(“INACA” compounds) is faster in both pHLM and pHHeps than their equivalent indole
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analogues (“ICA” compounds), e.g., 5F-MDMB-PINACA (2) vs. 5F-MDMB-PICA (3) and
MDMB-4en-PINACA (5) vs. MDMB-4en-PICA (12) (methyl 3,3-dimethyl-2-[1-(pent-4-en-1-
yl)-1H-indole-3-carboxamido]butanoate) (Tables 4 and 5).
Overall, these findings corroborate data from a number of previous studies: Franz et al.
(2019) [37] demonstrated that indoles were significantly less metabolically reactive than
their indazole analogues during in vitro pHLM studies; Hess et al. (2017) [65] demon-
strated that long term stability in non-frozen plasma (4 ◦C and 20 ◦C) was of the or-
der AB-FUBINACA = ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
(4-fluorobenzyl)-1H-indole-3-carboxamide) > MDMB-FUBINACA > AMB-FUBINACA;
Krotulski et al. (2020) [63] showed that the order of stability in non-frozen whole blood
was ADB-FUBINACA > 5F-MDMB-PICA > 5F-MDMB-PINACA > AMB-FUBINACA.
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(b) Differences in clearance of (S)-5F-MDMB-PINACA (2) and (S)-5F-AMB-PINACA (10) incubated
in pooled human cryopreserved hepatocytes (pHHeps) (n ≥ 3 ± SD).
The reactivity/lability of the methyl ester and amide moieties within the valinate and
tert-leucinate indole and indazole-3-carboxamide SCRAs appears to be the determining
step for their in vitro clearance rates, the type of metabolites formed in vitro and in vivo
and their stability ex vivo in whole blood and plasma. It is therefore logical that in both
this study and in other studies, AMB-FUBINACA (1) has been found to be among the
most metabolically unstable compounds studied. The reasons being that the methyl ester
oiety is funda entally unstable; there is little steric hindrance to slo do n enzy atic
hydrolysis of the methyl ester by esterases; the molecule is relatively more reactive due
to its indazole core compared to indole compounds, and other sites of metabolism on the
molecule are limited due to the presence of the stable fluorobenzyl moiety.
2.4.2. The Influence of Chirality on Intrinsic Clearance Rates and Half-Lives
As enantioselectivity is common in both metabolism and pharmacology [88], compari-
son of the intrinsic clearance and half-lives between enantiomer pairs can provide some
further fundamental information on the influence of structural and conformational features
on the molecular interactions between SCRA substrates and metabolic enzymes.
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There were some notable differences in the half-lives and intrinsic clearance derived
from the incubation of (R)- and (S)- enantiomers with pHLM (Table 4, Section S6 of the
supplementary information). For most compounds, the (S)-enantiomer was consistently
cleared at a faster rate than the (R)-enantiomer, particularly for AMB-FUBINACA (1) and
5F-AMB-PINACA (10).
For those compounds with an alkene tail (4en compounds), there was either no
difference between enantiomers (MDMB-4en-PINACA (5)) or the (R)-enantiomer was
cleared faster (AMB-4en-PICA (7) and MDMB-4en-PICA (12)). When SCRA enantiomer
pairs were incubated in pHHeps (Table 5, Section S7 of the supplementary information),
there was negligible difference between the derived half-lives and intrinsic clearance rates
of (S)- and (R)-enantiomers for AB-compounds. For AMB-compounds there was a marginal
difference between the intrinsic clearance and half-lives of the enantiomer pairs with (S)-
enantiomers cleared at a faster rate. tert-Leucine methyl ester SCRAs without an alkene tail
group (5F-MDMB-PINACA (2), 5F-MDMB-PICA (3), 4F-MDMB-BINACA (4) and MDMB-
FUBINACA (6)), showed the greatest difference in intrinsic clearance rates between the
(S)- and (R)-enantiomers, with the (S)-enantiomers consistently cleared at a faster rate.
Of the tert-leucine methyl ester SCRAs with an alkene tail group (-4en- compounds), the
(S)-enantiomer of MDMB-4en-PINACA (5) was cleared faster than the (R)-enantiomer but
the intrinsic clearance of the enantiomer pairs of AMB-4en-PICA (7) and MDMB-4en-PICA
(12) was similar.
In this study, the majority of pHHep incubations were carried out using hepatocytes
of a single lot number, however 5F-MDMB-PINACA (2) was tested using two different
lots of pHHep cells. In initial pHHep incubations (lot HUE50-N), incubation of (S)-5F-
MDMB-PINACA and (R)-5F-MDMB-PINACA (2) gave half-lives of 13.3 ± 3.4 min (n = 8)
and 22.9 ± 1.8 min (n = 6) respectively, while in pHHep lot HUE50-P, half-lives were
13.2 ± 3.4 min (n = 4) and 6.5 ± 0.13 min (n = 4), respectively. The increased clearance
of (R)-5F-MDMB-PINACA (2) in the latter incubation suggests a difference in expression
of enzyme(s) in this lot of cells, but no such differences were observed for the other
compounds tested (MDMB-4en-PINACA (5), MDMB-4en-PICA (12) and AMB-4en-PICA
(7)) using the two different pHHep lots.
2.4.3. Comparison of Intrinsic Clearance Calculated from pHLM and pHHeps
For all compounds, with the exceptions of (R)-5F-MDMB-PICA (3) and (R)-MDMB-
4en-PICA (12), intrinsic clearance scaled to whole-liver dimensions for pHHeps was faster
than or comparable to that of pHLM. For all MDMB- compounds, and for most (S)-
AMB-compounds differences in CLint were within 2.5-fold. Those containing an amide
(AB-compounds) rather than a methyl ester group, and thus forming an amide hydrolysis
product as a major metabolite [69,87], showed the greatest differences in intrinsic clearance
between pHLM and pHHeps but were cleared the slowest overall. There are multiple
factors which can cause intrinsic clearance by HHeps to differ from HLM [89]. Differences
may reflect the relative efficiency of transport of SCRAs and their enantiomers through
cell membranes in HHeps and the relative abundance of particular enzymes in HLM and
HHeps, targeting different sites of metabolism, particularly carboxylesterases. A domi-
nance of non-CYP enzymes in metabolic clearance can result in CLint being faster in HHeps.
The degree of Phase II glucuronidation thought to be produced from these drugs varies, but
glucuronidation here only occurs after some form of Phase I biotransformation and is gener-
ally minimal compared to other pathways [56,64,69–71,90]; these studies however did not
utilise metabolite reference standards or beta-oxidation for confirmation. Glucuronidation
is therefore unlikely to cause the differences in clearance rates observed. Carboxylesterase
enzymes are non-CYP enzymes, but are present in microsomes and do not require cofac-
tor [91]. CES-1 is one of the most abundant enzymes in human hepatocytes, present in the
endoplasmic reticulum and to a lesser extent in the cytosol [67,88,91]. Non-specific binding
of drugs to microsomes and hepatocytes results in a lower unbound fraction available
to interact with enzymes; differences in binding between HLM and HHep incubations
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may therefore also cause clearance differences [89]. Non-specific binding may be esti-
mated from log P data [92,93]. Theoretical fraction unbound for microsomes (fumic) and
hepatocytes (fuhep) was calculated using experimental pHLM and pHHep concentrations
and incubation volumes, and experimental log D7.4 values, as described by Kilford et al.
(2008) [92] with hepatocyte cell volume as 3.9 µL/million cells [94]. In this study, fumic
ranged from 0.18–0.82 (n = 12, median = 0.42), while fuhep ranged from 0.47–0.95 (n = 12,
median = 0.75). These results suggest in vivo hepatocyte binding is mostly limited (except,
perhaps for MDMB-4en-PINACA (5) (estimated fuhep 0.47)), while microsomal binding
is greater. However, differences in predicted binding did not necessarily correlate with
differences in clearance, so this is unlikely to be a significant factor.
2.5. Prediction of Human In Vivo Clearance
When PPB was considered in the prediction of in vivo hepatic clearance (see Table 3),
clearance rates were, as would be expected, much slower than in vitro values (Tables 4 and 5).
Hepatic clearance predicted from pHLM incubations ranged from 0.34 mL min−1 kg−1
((S)-AB-FUBINACA (8)) to 17.79 mL min−1 kg−1 ((S)-5F-AMB-PINACA (10)). Hepatic
clearance predicted from pHHep incubations ranged from 1.39 mL min−1 kg−1 ((S)-MDMB-
FUBINACA (6)) to 18.25 mL min−1 kg−1 ((S)-5F-AMB-PINACA (10)). Predicted in vivo
hepatic clearance from HLM in vitro data were calculated to allow comparison with avail-
able literature values. They should be viewed cautiously for SCRAs with a terminal ester
or amide moiety due to likely differences in CES-1 enzyme expression between pHLM
and pHHeps. However, in this study, no marked differences in predicted in vivo clearance
rates between pHLM and pHHeps were observed. SCRA clearance studies have previously
shown that true in vivo clearance is often slower than is predicted from in vitro data [15,95].
This is likely due to the lipophilicity and high degree of plasma protein binding of these
compounds; for most SCRAs, PPB has not previously been characterised and so was not
previously incorporated into the prediction of human in vivo rates. Hepatic clearance in
this study has been predicted according to the ‘well-stirred’ model, where fu may be based
on either blood or plasma binding data [79,96]. Here, plasma binding data were used
and so it is assumed that the blood/plasma ratio of the test compounds is 1. Differences
in binding in plasma versus whole blood could therefore influence the results. Hepatic
extraction ratios (Tables 4 and 5) showed large differences between the compounds tested.
The ratios ranged from 0.02 ((S)-AB-FUBINACA (8)) to 0.85 ((S)-5F-AMB-PINACA (10))
based on pHLM incubations, and from 0.07 ((S)-MDMB-FUBINACA (6)) to 0.87 ((S)-5F-
AMB-PINACA (10)) based on pHHep incubations. The fraction of drug predicted to be
cleared with each pass of the liver therefore varies greatly between compounds. Although
(S)-enantiomers tended to have faster intrinsic clearance rates in pHHeps, they also tended
to be slightly more protein bound than (R)-enantiomers; thus, predicted in vivo clearance
rates and hepatic extraction ratios were not substantially different between enantiomers.
For a small number of the SCRAs tested in this study, comparative intrinsic clear-
ance data are available in the literature (Table 6), and data reported here was in overall
agreement with the reported values. While studies of intrinsic clearance in pHHeps are
limited, more studies have reported microsomal rates. Although not reported, it is as-
sumed that the (S)-enantiomers have been tested in the literature studies. Castaneto et al.
reported AB-FUBINACA (8) CLint micr as 0.011 mL min−1 mg−1, with intrinsic clearance
of 10.5 mL min−1 kg−1 [69]. Presley et al. found 5F-MDMB-PINACA (2) CLint micr to be
0.271 mL min−1 mg−1, with an intrinsic clearance rate of 256.2 mL min−1 kg−1 [54]. These
findings are in line with data reported here. However, as protein binding studies were
unavailable at the time, CLH and EH predictions by Castaneto et al. and Presley et al. [54,69]
did not account for binding and so rates for this differ; based on pHLM incubations, CLH
and EH predictions for AB-FUBINACA (8) [69] were 20-fold and 17-fold lower respectively
when PPB was accounted for, while those for 5F-MDMB-PINACA (2) [54] were 4-fold
lower in this study. Intrinsic clearance of 5F-AMB-PINACA (10) and AMB-4en-PICA (7)
have also been reported previously, and both were similar to the data reported in this
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study [57,73]. Davidsen et al. (2010) [13] reported increasing metabolic stability of JWH-
type SCRAs in HHeps with increasing size of halogen atom incorporated into the structure,
with I-JWH-122 ((1-(5-iodopentyl)-1H-indol-3-yl)(4-methylnaphthalen-1-yl)methanone)
being the most metabolically stable. The effect of incorporation of fluorine onto the pentyl
tail group is unclear; for JWH-122 ((4-methyl-1-naphthyl)-(1-pentylindol-3-yl)methanone)
(HHeps) and AMB-PINACA (methyl (1-pentyl-1H-indazole-3-carbonyl)valinate) (HLM),
5-fluorination makes little difference to intrinsic clearance [13,73].
The 5-fluorination of Cumyl-PICA (1-pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-
carboxamide) (HLM) results in faster clearance [95], while 5-fluorination of AB-PINACA
(HLM) results in slower clearance [16]. As noted previously, the incorporation of fluo-
robenzene (e.g., FUB- or -FUBINACA compounds) tends to stabilise compounds, reducing
clearance rates [16,69,97].
In vivo hepatic clearance is related to both CLint and fu [79]; for many drugs, in-
creasing log P will increase CLint but reduce fu. Thus, the effect of log P on whole-body
clearance can be unpredictable. However, increasing log P can increase the volume of
distribution of the unbound fraction [79]. Although the majority of the SCRAs studied
here are rapidly metabolised in vitro, high levels of protein binding in vivo will extend
the time they will circulate in the body following consumption. This potentially facilitates
storage in lipid-rich tissues such as adipose tissue, particularly in chronic users. Detection
windows of some compounds have been reported to be exceptionally long following drug
cessation [43,98,99]. Franz et al. reported detection in urine of a metabolite common to
AB-FUBINACA (8) and AMB-FUBINACA (1) two years after reported cessation of con-
sumption, but did not determine which drug was responsible [43]. Hasegawa et al. (2015)
reported detection of AB-CHMINACA (11) and 5F-AMB-PINACA (10) in a fatal poisoning
case, where AB-CHMINACA (11) could be quantified in all solid tissues tested, while
5F-AMB-PINACA (10) could only be quantified in adipose tissue [98]. These data suggest
extensive redistribution of synthetic cannabinoids in vivo. Experimental data presented
here show hepatic clearance of AB-type SCRAs to be slower than that of MDMB- and AMB-
compounds, with lower hepatic extraction ratios. However, the SCRAs are not metaboli-
cally stable enough to explain the recently reported long detection windows. Therefore,
the presence of such compounds and their metabolites in body fluids after a considerable
time is more likely to be evidence of tissue accumulation, subsequent leaching back into
the circulatory system and metabolism of the unbound fraction. JWH- SCRAs have log P
values which are similar to or greater than those of indole- and indazole-3-carboxamide
SCRAs (and therefore likely similar or greater PPB), which may in part explain their ex-
tended detection windows in vivo [100,101], though specific structural features are likely
also involved [39].
2.6. Study Limitations
A limitation to this study, and indeed other research studies related to the metabolism
of constantly emerging SCRAs and other NPS using pHLM and pHHeps, is that it does
not consider the expected variation in metabolic capacity between individual users. The
aim of the study is, however, to provide comparative information for the metabolism of
structurally related SCRAs in an ‘average’ human using pooled donor in vitro platforms,
to allow the deconvolution of the key structural features of the SCRAs that affect metabolic
stability in isolation. The study provides a more accurate estimate of in vivo human
hepatic clearance than previously reported by taking into account the effect of plasma
protein binding. This is the first time such information has been incorporated into in vivo
hepatic clearance calculations for the SCRA structural classes studied. The study also
does not consider other potential sites of metabolism likely to be important in SCRAs
which are smoked or vaped, namely the lungs; no metabolic studies on SCRAs using
lung microsomes have yet been reported in the literature. Metabolism by the lungs could
occur to some degree as they contain numerous metabolising enzymes including, but
not limited to, carboxylesterases such as CES-1 (but at a lower concentration than the
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liver) [102], likely to be the main enzyme responsible for methyl ester and amide hydrolysis
of these SCRAs. The lungs also contain CYP450 enzymes as well as uridine 5′-diphospho-
glucuronosyltransferase (UGT) enzymes (but with limited expression compared to other
tissues) [103]. While Phase I metabolism in human lung parenchymal cells has shown
less than 10% the activity of that of cryopreserved human hepatocytes, levels of ester
hydrolysis, of great importance to the valinate- and tert-leucinate SCRAs included in this
study, have been shown to be similar [104]. Through inhalation of SCRAs, the lungs will
be exposed to high drug concentrations. It is unclear to what extent metabolism of valinate
and tert-leucinate indole and indazole-3-carboxamide SCRAs in the lungs may affect the
extent of SCRA biotransformation, and thus the bioavailability of the parent compound,
before reaching systemic circulation.
Table 6. Literature values for intrinsic clearance (CLint) rates and half-lives (t1/2) of SCRAs in human liver microsomes (HLM) and
human hepatocytes (HHeps). Compounds marked with an asterisk (*) display pHHep data; all other data is from pHLM incubations.
Compound HLM/HHeps * ReferenceCLint micr (mL min−1 mg−1) CLint (mL min−1 kg−1) t1/2 (min)
JWH-122 * - 1350 0.95
[13]
MAM-2201 * - 1408 0.88
Cl-JWH-122 * - 502 2.46
Br-JWH-122 * - 497 2.49
I-JWH-122 * - 235 5.26
AM1220 * - 169 3.7 [105]
THJ-018 0.036 34.2 19.2
[14]THJ-2201 0.064 60.8 10.8
NNEI 0.300 350 2.29
[15]MN-18 0.410 469 1.71
NM-2201 0.088 81.6 8.0 [106]
BIM-2201 0.142 134.1 4.9 [107]
Cumyl-PICA 0.12 - 5.92
[95]5F-Cumyl-PICA 0.39 - 1.77
STS-135 0.222 209 3.1 [108]
AMB-4en-PICA (7) - 291 2.1 [57]
AB-PINACA 0.037 35 18.7
[16]5F-AB-PINACA 0.019 18 35.9
AMB-PINACA - 1.1
[73]5F-AMB-PINACA (10) 0.67 - 1.0
5F-MDMB-PINACA (2) 0.271 256.2 3.1 [54]
5F-APP-PICA 0.046 - 15.1
[109]5F-APP-PINACA 0.202 - 3.4
APP-CHMINACA 0.133 - 5.2
AB-FUBINACA (8) 0.011 10.5 62.6 [69]
ADB-FUBINACA 0.018 16.5 39.7 [17]
FDU-PB-22 0.056 52.7 12.4
[97]FUB-PB-22 0.060 57.1 11.5
3. Materials and Methods
3.1. Chemicals and Reagents
The in-house enantiospecific synthesis of the (R)- and (S)-enantiomers of AMB-
FUBINACA (1) (>98% purity), 5F-MDMB-PINACA (5F-ADB) (2) (>99.6% purity), 5F-
MDMB-PICA (3) (>99% purity), 4F-MDMB-BINACA (4) (>99.7% purity), MDMB-4en-
PINACA (5) (>98.6% purity), MDMB-FUBINACA (6) (>99.9% purity), AMB-4en-PICA (7)
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(>99.7% purity), AB-FUBINACA (8) (>99% purity), AMB-CHMICA (9) (MMB-CHMICA)
(>99.6% purity), 5F-AMB-PINACA (10) (5F-AMB) (>99.9% purity), AB-CHMINACA
(11) (>99% purity) and MDMB-4en-PICA (12) (>99.7% purity) has been described pre-
viously [1,31].
Donepezil, verapamil, 7-ethoxycoumarin (7-EC), bis(4-nitrophenyl) phosphate (BNPP),
phenyl methyl sulphonyl fluoride (PMSF), procaine, warfarin, nicardipine, nicotinamide
adenine dinucleotide phosphate (NADP), reduced NADP (NADPH), glucose-6-phosphate
dehydrogenase (from baker’s yeast S. cerevisiae), D-glucose-6-phosphate sodium salt,
sodium bicarbonate, potassium phosphate buffers (monobasic and dibasic), formic acid
(99%) and dimethylsulfoxide (DMSO) were purchased from Sigma-Aldrich (Gillingham,
UK). 7-hydroxycoumarin (7-HC) was purchased from Chem Service (West Chester, PA,
USA). Analytical grade acetonitrile (ACN) and methanol (MeOH) were purchased from
Sigma-Aldrich or Greyhound Chromatography (Birkenhead, UK).
Ultra-high purity water (18 MΩ cm−1) was obtained using a Milli-Q water purification
system (Merck, Livingston, UK). Human plasma (pooled; Na EDTA anticoagulant; lot
numbers 27079, IR07-081) (Innovative Research (Novi, MI, USA)) was purchased from
Patricell (Nottingham, UK)). Pooled human liver microsomes (pHLM, donor pool 50, lots
PL050E-A, PL050E-B with epidemiological information available for all donors [110,111]),
pooled cryopreserved human hepatocytes (pHHeps, donor pool 50, lots HUE50-N, HUE50-
P with epidemiological information available for all donors [112,113]), Williams Media E
(WME) (without glutamine or phenol red), cell maintenance supplement pack (with Cock-
tail B/Dexamethasone), trypan blue and cryopreserved hepatocyte recovery medium were
purchased from Gibco (ThermoFisher Scientific, Waltham, MA, USA). pHLM preparations
were incubated in a Stuart S160 benchtop incubator with shaking on a Stuart SSM1 mini
orbital shaker (Cole-Parmer, St. Neots, UK). pHHep preparations were incubated in a
Thermo Scientific HERAcell Vios 160i CO2 incubator, with shaking on a Thermo Scientific
CO2 resistant orbital shaker (Fisher Scientific, Loughborough, UK). Individual reference
standard stock solutions were prepared at 1–10 mM in DMSO depending on purpose and
stored at −20 ◦C until use, unless used immediately. Working solutions were prepared on
the day of use.
3.2. Instrumentation
Chromatographic hydrophobicity index (CHI) log D samples (see below) were anal-
ysed using high-performance liquid chromatography (HPLC) with a Shimadzu Nexera X2
HPLC coupled to a Shimadzu SPD-30 MA photodiode array detector (PDA) (Shimadzu,
Kyoto, Japan). Data analysis was performed using Shimadzu LabSolutions 5.91 software.
Samples (2 µL) were injected onto an Acquity BEH C18 column (2.1 × 50 mm2, 1.7 µm)
(Waters Corp., Milford, MA, USA) at a flow rate of 0.6 mL min−1 at 25 ◦C. The sample
chamber was maintained at 25 ◦C. Gradient elution was performed, with mobile phase
(MP) consisting of ammonium acetate in water (10 mM, pH 7.4) (MP A) and acetonitrile
(MP B). The following gradient was used: 0–4.0 min from 5% B to 95% B, 4.0–4.5 min hold
95% B, 4.5–4.51 min to 5% B, 4.51–5.51 min hold 5% B. Detection was achieved by scanning
over a range of 190 to 500 nm wavelength, with 254 nm used for identification and peak
area normalisation.
In vitro incubation samples (see below) were analysed using ultra-performance liq-
uid chromatography-tandem mass spectrometry (UPLC-MS/MS) with a Waters Acquity
UPLC coupled to a Waters Xevo TQ-S micro tandem mass spectrometer (Waters Corp.,
Milford, MA, USA). Data analysis was performed using Waters Masslynx 4.1 software
(Waters Corp.). Samples (1 µL) were injected onto an Acquity UPLC BEH C18 column
(2.1 × 50 mm2, 1.7 µm) (Waters Corp.) at a flow rate of 0.6 mL min−1 at 45 ◦C. The sample
chamber was maintained at 4 ◦C. Gradient elution was performed, with mobile phases
(MP) consisting of water with formic acid (0.01% v/v, MP A) and methanol with formic
acid (0.01% v/v, MP B). The following gradient was used: 0–0.3 min 5% B, 0.3–1.3 min to
95% B, 1.3–1.79 min hold 95% B, 1.79–1.8 min to 5% B. MS acquisition was achieved with
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positive electrospray ionisation (ESI) and the MS operating in MRM mode, with MRM
transitions provided in Section S1 of the supplementary information. The following MS
parameters were used: source temperature 100 ◦C, desolvation gas 500 ◦C at a flow rate
of 1000 L h−1, cone gas flow rate 50 L h−1, collision gas (nitrogen) at 0.3 mL min−1, cone
voltage was 44 V and capillary voltage was 3.40 kV.
3.3. In Silico Log P Prediction
Log P values were predicted for all SCRAs tested in this study using multiple software
packages, with the full dataset provided in Section S2 of the supplementary information.
Software packages used were SwissADME (Swiss Institute of Bioinformatics, Lausanne,
Switzerland; online and free to access), Gastroplus (SimulationPlus, Lancaster, CA, USA;
MedChem Designer version 4.5), MoKa (Molecular Discovery, Borehamwood, UK; version
3.0), Canvas (Schrödinger, LLC, New York, NY, USA; version 3.6) and XlogP (Institute of
Physical Chemistry, Peking University [114]).
3.4. Experimental Log D7.4
Log D (pH 7.4) was determined by chromatographic hydrophobicity index (CHI)
measurements for the (S)-enantiomer of each SCRA involved in this study. A calibration
mix of ten compounds at 10 µg mL−1 in 1:1 (v/v) water:ACN was used (theophylline,
phenyltetrazole, benzimidazole, colchicine, phenyltheophilline, acetophenone, indole,
propiophenone, butyrophenone and valerophenone (all Sigma-Aldrich)). Test compounds
were prepared at 0.25 mM in 1:1 (v/v) water:ACN. Samples (n = 2 for calibration standards;
n = 1 for test compounds) were analysed using UPLC-PDA as described above. Retention
times of calibration compounds are used to calculate retention factor (k), which is plotted
against literature CHI values for each compound. Linear regression was performed to
obtain a line of best fit, from which the CHI and subsequently CHI log D of calibration
and test compounds are calculated. Calculations used and calibration data from CHI log D
studies are provided in Section S3 of the supplementary information.
3.5. Plasma Stability Studies
The pooled plasma used for both plasma stability and plasma binding studies orig-
inated from 50 donors, collected as whole blood from donors in the United States at an
FDA-approved collection center, processed into plasma by centrifugation and immediately
frozen (Innovative Research; Novi, MI, USA) and purchased from Patricell (Nottingham,
UK). Plasma was tested by the manufacturers for a range of FDA-required viral markers.
Pooled human plasma, was centrifuged (3750 rpm, 10 min, 22 ◦C) and the supernatant
buffered to pH 7.4 by diluting to 70:30 plasma to potassium phosphate buffer (50 mM,
pH 7.4). Stock solutions were prepared in DMSO. For inhibitor incubations, esterase
inhibitors BNPP and PMSF were added to plasma mixture to give final concentrations
of 500 µM for each. For incubations without inhibitor an equivalent volume of DMSO
was included. Plasma mixture was pre-incubated at 37 ◦C for 5 min. Test compounds
(5 µM) and procaine (positive control, 50 µM) were added to pre-warmed plasma mixture
containing inhibitors. Incubation volume was 1 mL. Samples were mixed and 80 µL was
immediately sampled and quenched into 200 µL ACN spiked with donepezil (internal
standard (IS), 50 ng mL−1). Plates were incubated at 37 ◦C with shaking (100 rpm) and
additional aliquots were sampled at 10, 30, 60, 120 and 180 min. (S)-AMB-FUBINACA
(1) was further sampled at 240 and 300 min as instability in plasma has been reported
previously [63]. Samples were centrifuged (3750 rpm, 10 min, 22 ◦C) and the supernatant
(150 µL) diluted with 50 µL deionised water before analysis by UPLC-MS/MS. Peak area
ratio of analyte to IS was used to determine half-lives of test compounds in plasma, both
with and without the presence of esterase inhibitors.
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3.6. Plasma Protein Binding
Plasma protein binding was assessed by equilibrium dialysis in a 96-well dialysis block
(HTDialysis, Ledyard, CT, USA). Dialysis membranes (12–14 kDa) were soaked in deionised
water for at least 60 min. Membranes were soaked overnight at 4 ◦C in ethanol:water 20:80%
v/v and then rinsed with deionised water immediately prior to use. Pooled human plasma
(Innovative Research, Novi, MI, USA) was centrifuged (3750 rpm, 10 min, 22 ◦C), spiked
with analyte at 10 µg mL−1 and allowed to equilibrate at room temperature (22 ◦C) for
20 min. Nicardipine and warfarin were included as positive controls. Spiked plasma
(150 µL) was dialysed against isotonic phosphate buffer (pH 7.4) (150 µL) for 5 h at 37 ◦C
with shaking at 100 rpm. Thermal degradation controls for each test compound were
kept at 37 ◦C and 4 ◦C. Blank control plasma and buffer were included in the incubation.
Following incubation, dialysed plasma samples and thermal degradation controls (50 µL)
were added to drug-free buffer (50 µL), and dialysed buffer samples (50 µL) were added to
drug-free plasma (50 µL). ACN (200 µL) containing donepezil (IS, 50 ng mL−1) was added
to each sample and samples were centrifuged (3750 rpm, 10 min, 22 ◦C). Supernatant
(150 µL) was added to 50 µL deionised water and samples were analysed by UPLC-MS/MS
as described above. Dialysed buffer from each well was tested for protein contamination
using BCA protein assay reagent to determine whether membranes had been compromised.





where Pl = Analyte/IS ratio determined in plasma side
Bu = Analyte/IS ratio determined in buffer side




3.7. Metabolic Stability—Pooled Human Liver Microsome Incubations
Test compounds and verapamil (positive control) were incubated at 0.5 µM in pHLM
(0.5 mg microsomal protein mL−1) incubations. Total incubation volume was 500 µL.
Procedure: Test compound working solutions (50 µM in potassium phosphate buffer
(pH 7.4)) were prepared (<1% DMSO). pHLM were thawed and diluted in potassium
phosphate buffer (pH 7.4). Drug working solution (5 µL) in phosphate buffer (50 µM, final
concentration 0.5 µM) and 445 µL microsome suspension (final concentration 0.5 mg mL−1)
were pre-incubated at 37 ◦C for 5 min, and 50 µL 8 mg mL−1 NADPH in phosphate
buffer (final concentration 0.8 mg mL−1) was used to initiate the reaction. Plates were
incubated at 37 ◦C with shaking (100 rpm) and samples (50 µL) collected at 0, 3, 6, 9, 15,
30 min. Reactions were quenched in 200 µL ACN spiked with donepezil (IS, 50 ng mL−1).
Samples were diluted with 50 µL deionised water and sealed and centrifuged (3750 rpm,
10 min, 22 ◦C) to sediment any precipitated proteins. Samples were analysed by UPLC-
MS/MS in a 96 deep-well 2 mL plate. Each SCRA was incubated at least in triplicate but
additional incubations were carried out across a number of analytical batches, giving greater
replication and a greater understanding of system variability. Microsomal scaling factors
used for human liver microsome incubations in the literature vary. Intrinsic clearance and
predicted in vivo clearance rates calculated using alternative scaling factors found in the
literature is provided in Section S6 of the supplementary information, to aid comparison of
data between publications.
3.8. Metabolic Stability—Pooled Human Cryopreserved Hepatocyte Incubations
Test compounds and positive controls (verapamil, 7-ethoxycoumarin (7-EC) and 7-
hydroxycoumarin (7-HC)) were incubated at 0.5 µM in pooled human cryopreserved
hepatocytes (pHHeps, 50 donor pool, 0.25 million cells mL−1). Total incubation volume
was 400 µL. Procedure: Cells were thawed and added to cryopreserved hepatocyte recovery
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media, centrifuged (100× g, 10 min, 22 ◦C), counted and diluted in WME (37 ◦C, bubbled
with 5% CO2:95% O2). To initiate reactions, 200 µL of drug working solution (1 µM) was
added to 200 µL cell suspension (0.5 million cells mL−1). Samples were mixed and 20 µL
sampled immediately and added to 80 µL ACN containing donepezil (IS, 50 ng mL−1) in
a 96 deep-well 2 mL plate. Plates were incubated at 37 ◦C with 5% CO2 with agitation at
95 rpm. Further aliquots were taken at 3, 6, 9, 15, 30, 45, 60 min. Samples were diluted with
100 µL of water/ACN (80:20 v/v) and centrifuged (2800 rpm, 10 min, 22 ◦C) prior to UPLC-
MS/MS analysis. Each SCRA was incubated at least in triplicate but additional incubations
were carried out across a number of analytical batches, giving greater replication and a
greater understanding of system variability. Differing values for hepatocyte cell density
are reported in the literature. Intrinsic clearance and predicted in vivo clearance rates
calculated using an alternative hepatocyte cell density is provided in Section S7 of the
supplementary information, to aid comparison of data between publications.
Rate constants (k, min−1) and half-lives (t1/2) were calculated using XLfit 5.3.1 add-in
(IDBS, Surrey, UK) for Microsoft Excel 2013, version 15.0 (Microsoft, Redmond, WA, US),
calculated from plots of analyte/IS peak area ratio against time. Microsomal intrinsic
clearance (CLint micr) (pHLM data) and intrinsic clearance (CLint) scaled to whole-liver
dimensions for humans (pHLM and pHHeps data) were calculated from k, liver and body
weight estimates and scaling factors [13,96,116]. Hepatic clearance (CLH) and extraction
ratios (EH) were estimated based on the corresponding human CLint values, fraction
unbound and estimates of liver blood flow rate (human 21 mL min−1 kg−1) [96,117,118].
The equations used for in vitro intrinsic clearance calculations and human in vivo
clearance estimation were as described by Baranczewski et al. (2006) [96], Rane, Wilkinson
& Shand (1977) [117] and Obach et al. (1997) [118] and are provided in Section S4 of the
supplementary information.
4. Conclusions
Many pharmacokinetic studies on SCRAs investigate metabolite formation as an
aid to toxicological analysis and interpretation. Determination of intrinsic clearance of
SCRAs by pHLM is also relatively common. However, few investigate SCRA clearance by
HHeps or account for other pharmacokinetic parameters such as plasma stability or protein
binding, or compare the clearance rates for a range of SCRAs of closely related structural
classes in the same study. Here, for the first time, human in vivo clearance predictions are
provided for valinate and tert-leucinate indole- and indazole-3-carboxamide SCRAs based
on experimentally derived PPB data and in vitro intrinsic clearance by both pHLM and
pHHeps. These compounds are lipophilic and highly protein bound, and so the parent
compounds of many may only be present in authentic urine samples in small proportions
compared to their metabolites. The results presented here support reports that, although
some of these compounds are relatively unstable in vitro, as they are highly plasma protein
bound the parent drug is likely stored in the adipose tissue of chronic users and may be
detectable for an extended duration in plasma and urine following redistribution.
Overall, the tested SCRAs were cleared rapidly in vitro in both pHLM and pHHeps;
(S)- enantiomers were cleared at a faster rate than (R)- enantiomers, except for compounds
containing an alkene tail group when incubated in pHLM. Between compounds, the head
group of the molecule is the one of the most important rate-determining factors, with valine
(dimethyl) methyl ester (AMB-) compounds cleared the fastest, followed by tert-leucine
(trimethyl) methyl ester (MDMB-) compounds, and with valinamide (dimethyl) (AB-)
compounds cleared at the overall slowest rate. Once PPB data were considered, predicted
in vivo hepatic clearance rates were much slower than in vitro intrinsic clearance. Despite
some observed differences in intrinsic clearance between enantiomers, once protein binding
was accounted for predicted whole-body clearance rates and hepatic extraction ratios were
comparable between enantiomers. Predicted in vivo rates however varied widely between
compounds suggesting that these compounds will be present in the circulatory system for
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varied durations, and thus may have varied durations of action, creating uncertainty for
users where the specific drug as well as dose present is unknown.
Supplementary Materials: The following are available online: Section S1: Table S1: Multiple reaction
monitoring (MRM) transitions for tested synthetic cannabinoid receptor agonists. Section S2: Table
S2: In silico Log P predictions using various software packages. Section S3: Equations and literature
chromatographic hydrophobicity index data used in determining CHI Log D values, Table S3:
Literature chromatographic hydrophobicity index (CHI) values (CHI0), Figure S1: Plot of retention
factor (k) against CHI0. Section S4: Equations used for in vitro intrinsic clearance calculation and
human in vivo hepatic clearance estimation. Section S5: Figures S2–S20: Plasma stability study
data. Section S6: Figures S21–S33: Graphical representation of intrinsic clearance data—human liver
microsome incubations, Table S4–S30: Intrinsic clearance data—human liver microsome incubations.
Section S7: Figures S34–S49: Graphical representation of intrinsic clearance data—human hepatocyte
incubations, Table S31–S58: Intrinsic clearance data—human hepatocyte incubations.
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